Project Grant R01CA299259
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $545K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- Federal Grant Award Summary The University of Michigan's Regents received a $646,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective March 11, 2026 through February 28, 2031. This award supports fundamental and applied research focused on developing novel multi-targeted therapeutic strategies to address chemotherapy-resistant T-cell lymphomas (TCL) and their tumor microenvironment. The research investigates...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $139,968 under the Cancer Research Manpower program (CFDA 93.398) on July 15, 2025, for a project period extending through June 30, 2027. This Project Grant supports biomedical research training and cancer-related research in basic and translational science aligned with the National Cancer Program priorities. The award funds a research initiative titled "Beyond Lysis:...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $136,412 to the Regents of the University of Michigan, effective August 1, 2025 through July 31, 2027, under the Cancer Research Manpower program (CFDA 93.398). This award funds research aimed at defining and interrupting metabolic crosstalk in the glioblastoma microenvironment. The research builds upon preliminary findings demonstrating that glioblastoma (GBM) tumors acquire nutrients through...
- Federal Grant Award Summary The National Cancer Institute awarded $2.82 million to the Regents of the University of Michigan under the Cancer Treatment Research program (CFDA 93.395) on August 6, 2025, with completion targeted for July 31, 2029. This Project Grant supports the development of new methods to measure metabolic pathway activity in glioblastomas (GBMs), deadly brain cancers that rewire their metabolism to enable growth, invasion, and treatment resistance. The research deliverables...
- The National Cancer Institute awarded the Regents of the University of Michigan a $669,278 Project Grant effective June 1, 2026, through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research initiative develops microbial-based cancer therapy utilizing nonpathogenic, tumor-tropic Escherichia coli engineered to display membrane-anchored immune cytokines, specifically decoy-resistant interleukin-18, to enhance localized immune activation within solid tumors while...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel microbial-based therapeutic strategy targeting colibactin, a carcinogenic metabolite produced by pathogenic gut bacteria associated with colorectal cancer (CRC). The project, which commenced September 10, 2025, and extends through August 31, 2029, focuses on engineering...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $175,448 under the Cancer Research Manpower program (CFDA 93.398) on January 16, 2026, with completion targeted for July 31, 2027. This project grant supports research training and investigator development in cancer biology, specifically focused on characterizing cancer-associated fibroblasts (CAFs) and their role in pancreatic ductal adenocarcinoma (PDAC). The research aims to...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- The University of Michigan received a $646,671 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, for research extending through April 30, 2031. The grant funds research to identify and characterize novel payloads for antibody-drug conjugates (ADCs) that maximize multiple mechanisms of action, including immunogenic cell death and Fc-effector function. The project specifically develops high avidity low affinity...